Prognostic Value of Proteolysis Indexes in the Formation of Diabetic Retinopathy

Main Article Content

S.V. Ziablitsev
O.V. Korobova
O.V. Petrenko
V.M. Serdiuk
S.Yu. Mohylevskyi


The article presents the results of the study on the violations in the proteolysis system of patients with type 2 diabetes mellitus (DM) and diabetic retinopathy (DR). We have evaluated the levels of matrix metalloproteinase‑9 (MMP‑9) and tissue inhibitor of matrix metalloproteinase‑1 (TIMP‑1) in the blood and in the aqueous humor (AH) of patients with type 2 DM by means of immunoenzyme method (Bender Medsystems, Austria). The changes in proteolysis system were detected in patients with DR and type 2 DM, they consisted in the increase in the levels of MMP‑9 and TIMP‑1 in the blood and AH in patients both with no signs of DR and with any its stage, compared to the levels of these parameters in patients without diabetes. It was found that MMP‑9 level in the AH and DM type 2 duration have an impact on the probability of developing diabetic macular edema (DME). At the level of MMP‑9 ≥ 105 ng/ml and duration of type 2 DM ≥ 10 years, the risk of developing DME is 100 %. The probability of proliferative DR in patients with type 2 DM over four years of follow-up is influenced: by the level of MMP‑9 in the AH, stage of DR at baseline and duration of DM type 2. When the level of MMP‑9 is ≥ 100 ng/ml, type 2 DM duration ≥ 10 years and there are no signs of DR at the beginning of the observation, the probability of proliferative DR is 85.9 %.

Article Details

How to Cite
Ziablitsev, S., O. Korobova, O. Petrenko, V. Serdiuk, and S. Mohylevskyi. “Prognostic Value of Proteolysis Indexes in the Formation of Diabetic Retinopathy”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 3.75, June 2016, pp. 32-36, doi:10.22141/2224-0721.3.75.2016.76628.
Original Researches


Evrosimovska B, Velickovski B, Dimova C, Veleska-Stefkovska D. Matrix metalloproteinases (with accent to collagenases). Journal of Cell and Animal Biology. 2011;5(7):113-120.

Raffetto JD, Khalil .A. Matrix Metalloproteinases and their Inhibitors in Vascular Remodeling and Vascular Disease. Biochemical Pharmacology. 2008;75(2): 346-359. doi: 10.1016/j.bcp.2007.07.004.

Nagase H, Woessner JF. Matrix metalloproteinases. The Journal of Biological Chemistry. 1999; 274: 21491-21494. doi: 10.1074/jbc.274.31.21491.

Giebel SJ, Menicucci G, McGuire PG. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Laboratory Investigation. 2005; 85 (5): 597-607. doi: 10.1038/labinvest.3700251.

Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Frontiers in Bioscience. 2006;11:1696-1701.

Rogowicz A, Zozulińska D, Wierusz-Wysocka B. Role of matrix metalloproteinases in the development of vascular complications of diabetes mellitus – clinical implications. Polskie Archivum Medycyny Wewnętrznej. 2007;117 (3):1-7.

Bhatt LK, Addepalli V. Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. American Journal of Translational Research. 2010; 2 (2):181-189.

Kowluru RA, Mohammad G, dos Santos JM, Zhong Q. Abrogation of MMP-9 Gene Protects Against the Development of Retinopathy in Diabetic Mice by Preventing Mitochondrial Damage. Diabetes. 2011;60(11):3023-3033. doi: 10.2337/db11-0816.

Derosa G, D’Angelo A, Tinelli C. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metabolism. 2007;33(2):129-134. doi: 10.1016/j.diabet.2006.11.008.

Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East African Journal of Ophthalmology. 2012;19 (1):52-59.

Kowluru RA. Role of Matrix Metalloproteinase-9 in the Development of Diabetic Retinopathy and Its Regulation by H-Ras. Investigative Ophthalmology Visual Science. 2010;51(8):4320-4326. doi: 10.1167/iovs.09-4851.

Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian Journal of Ophthalmology. 2012; 60 (5):428-431. doi: 10.4103/0301-4738.100542.

El-Azab MF, Mysona BA, El-Remessy AB. Statins for prevention of diabetic-related blindness: a new treatment option? Expert Review of Ophthalmology. 2011; 6 (3): 269-272. doi: 10.1586/eop.11.36.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice. 2010; 87 (1): 4-14.

International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015.

Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. The International Journal of Biochemistry and Cell Biology. 2006; 38: 752-765. doi: 10.1016/j.biocel.2005.08.002.

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010; 376 (9735): 124-136. doi: 10.1016/S0140-6736(09)62124-3.

Тron’ko МD, Sokolova L.К., Vlasenko МV, Коstiukevich А.А. An achievement of aims of treatment patients is with a diabetes mellitus in Ukraine. Results of International research are from the study of practice of conduct of diabetes mellitus (IDMPS). Endocrinology. 2015; 20 (4): 658-668. Ukrainian.

Kowluru RA, Zhong Q, Santos JM. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs. 2012; 21 (6): 797-805. doi: 10.1517/13543784.2012.681043.

Demirel S, Argo C, Agarwal A. Updates on the Clinical Trials in Diabetic Macular Edema. Middle East African Journal of Ophthalmology. 2016; 23 (1): 3-12.

Wilkinson CP, Frederick L, Ferris MI, Klein RE. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110 (9): 1677-1682.

Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012; 32 (10): 2150-2157. doi: 10.1097/IAE.0b013e3182576d07.